Novel Targets for Cardiac Antiarrhythmic Drug Development
| Autor: | John Christian Hesketh, Stanley Nattel, Stephen Zicha, Daniel Herrera |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pharmacology
Proarrhythmia medicine.medical_specialty business.industry medicine.medical_treatment Action Potentials Cardiac arrhythmia Arrhythmias Cardiac Cardiac mortality Antiarrhythmic agent medicine.disease Ion Channels Pharmacotherapy Drug development Drug Design Drug Discovery cardiovascular system Humans Technology Pharmaceutical Medicine business Intensive care medicine Anti-Arrhythmia Agents |
| Zdroj: | Current Pharmaceutical Design. 11:1959-1974 |
| ISSN: | 1381-6128 |
| DOI: | 10.2174/1381612054021051 |
| Popis: | Cardiac arrhythmias remain a major source of morbidity and mortality in developed countries. Antiarrhythmic drug therapy was traditionally the mainstay of cardiac arrhythmia treatment; however, drug therapy of cardiac arrhythmias has been plagued by incomplete efficacy and by potentially serious adverse reactions, of which the most worrisome has been a potential for malignant proarrhythmia and related effects to increase cardiac mortality. This article reviews the principal arrhythmia mechanisms and their ionic determinants, and discusses potential innovative approaches to new antiarrhythmic drug development, including the consideration of novel ionic targets, potential biophysical approaches and non-channel components involved in composing the arrhythmic substrate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|